バイオベンチャー列伝2(週刊東洋経済eビジネス新書No.139)
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
1 credit a month to buy any audiobook in our entire collection.
Access to thousands of additional audiobooks and Originals from the Plus Catalogue.
Member-only deals & discounts.
Auto-renews at $16.45/mo after 30 days. Cancel anytime.
バイオベンチャー列伝2(週刊東洋経済eビジネス新書No.139)
Narrated by:
海老塚 久蔵
Buy Now for $12.99
No valid payment method on file.
We are sorry. We are not allowed to sell this product with the selected payment method
Pay using voucher balance (if applicable) then card ending in
By confirming your purchase, you agree to Audible's Conditions Of Use and Privacy Notice and authorise Audible to charge your designated credit card or another available credit card on file.
-
Narrated by:
-
海老塚 久蔵
-
By:
-
週刊東洋経済編集部
About this listen
米国で設立後に日本で上場、中国で創薬を行う異色ベンチャー・ジーエヌアイグループ、遺伝子治療薬の開発を行うアンジェス ＭＧ、がん治療薬を開発するナノキャリア……。
創薬系バイオベンチャー企業は高い成長が期待できる反面、新薬開発には長い?月と多額の研究費用を要するうえに、すべての開発が成功するとは限らず、リスクも高い。
はたして今回紹介する中から大化けする企業は出てくるのか!?
本書は、東洋経済新報社のサイト「会社四季報オンライン」に掲載された連載「大化け創薬ベンチャーを探せ！」を加筆修正のうえ制作しています。
©東洋経済新報社 (P)2019 Audible, Inc.
What listeners say about バイオベンチャー列伝2(週刊東洋経済eビジネス新書No.139)
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.